IC
RGLS

Ikarian Capital’s Regulus Therapeutics RGLS Stock Holding History

Ikarian Capital’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-105,341
Closed -$217K – 153
2022
Q2 		$217K Sell
105,341
-23,572
-18% -$57.2K 0.04% 117
2022
Q1 		$384K Buy
128,913
+6,071
+5% +$15.8K 0.05% 145
2021
Q4 		$388K Hold
122,842
– – 0.06% 141
2021
Q3 		$849K Sell
122,842
-1,757
-1% -$12.9K 0.06% 161
2021
Q2 		$1.01M Hold
124,599
– – 0.08% 159
2021
Q1 		$1.94M Buy
+124,599
New +$1.84M 0.07% 200

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ikarian Capital's RGLS Position: Q3 2022 in Review

Ikarian Capital sold out of Regulus Therapeutics (RGLS) in Q3 2022, closing a stake of 105,341 shares — an estimated $217K sold.

Ikarian Capital first reported a position in RGLS in Q1 2021 and held it in 6 quarters. The position peaked at $1.94M in Q1 2021. 24 funds tracked by Wall St. Rank hold RGLS as of Q3 2022.

  • Ikarian Capital reported no remaining Regulus Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Ikarian Capital sold 105,341 Regulus Therapeutics shares in Q3 2022, an estimated $217K.
  • Ikarian Capital first reported a position in Regulus Therapeutics in Q1 2021 and held it in 6 quarters.
  • Ikarian Capital's Regulus Therapeutics position peaked at $1.94M in Q1 2021.
  • 24 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2022.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.